Avacta Group progresses to final cohort in Phase 1a study of AVA6000
Avacta Group plc (AIM: AVCT), a leader in the life sciences sector specializing in innovative oncology drugs and diagnostics, has announced the completion of its sixth dose escalation cohort in the ALS-6000-101 Phase 1 clinical trial. The study aims to evaluate the safety and tolerability of AVA6000, a chemically modified form of doxorubicin, in patients […]